ClinicalTrials.gg
CompletedNCT05864105Updated Jul 9, 2026

PM8002 in Combination With Chemotherapy as First Line Therapy in Hepatocellular Carcinoma

A Phase 2 interventional study of PM8002 and FOLFOX regimen in Hepatocellular Carcinoma, sponsored by Biotheus Inc.. Completed at 9 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-09.

Sponsored by Biotheus Inc. (part of BioNTech SE) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Apr 2022, registered May 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
35
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,310 studies in Carcinoma, Hepatocellular with a site in China — 486 open to participants now, 558 under way, 70 of them phase 3. Carcinoma, Hepatocellular · China.

Enrollment
741st of 1,034
35 · median 78
Started
2022
with 110 others
Phase 2
331 of 1,310
144 open now
Registered
818th of 1,310
by date

Among the 1,310 studies in Carcinoma, Hepatocellular with a site in China, this one is the 741st largest by enrollment of the 1,034 interventional ones that give a count, is one of 111 that started in 2022, is one of 331 in phase 2, and was the 818th registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

486 of the 1,310 studies in Carcinoma, Hepatocellular with a site in China are open now. Recruiting first, the newest first:

481 more — sign in →

All 486 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,310 studies in Carcinoma, Hepatocellular with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, single-arm, open-label phase II study to evaluate the efficacy and safety of PM8002 in combination with chemotherapy in the first-line treatment of subjects with inoperable HCC.

Read the detailed description

PM8002 is a Bispecific Antibody Targeting PD-L1 and VEGF.

03

Conditions studied

  • Hepatocellular Carcinoma

Keywords

  • PD-L1/VEGF
  • FOLFOX-4
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntary participation in clinical study; fully understand the study and sign voluntarily; willing to follow and able to complete all test procedures;
  2. Male or female aged >= 18 years;
  3. HCC diagnosed by pathology or clinical;
  4. BCLC stage C or B (unresectable or/and not suitable for local therapy);
  5. score \<= 7;
  6. performance status of 0 or 1.

Exclusion criteria

Exclusion Criteria:

  1. Histological diagnosis of fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC;
  2. Symptomatic , not suitable for the study assessed by investigator;
  3. Evidence of major coagulopathy or other obvious risk of bleeding;
  4. Unable to accept enhanced imaging examination (CT or MRI) for any reason;
  5. History of severe allergic disease, severe allergy to drugs or known allergy to any component of the drug in this study;
  6. infection or known acquired immunodeficiency syndrome;
  7. Known history of allogeneic organ transplantation or hematopoietic stem cell transplantation;
  8. Known history of alcohol abuse, psychotropic drug abuse or drug abuse;
  9. Patients with psychiatric disorders or poor compliance;
  10. Women who are pregnant or breastfeeding;
  11. The condition of the subject, as determined by the investigator, may increase the risk of after study treatment, or may cause confusion about the interpretation of the toxic reaction and AE;
  12. Other conditions lead to inappropriate to participate in this study as judged by the investigator.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    PM8002+FOLFOX-4

    PM8002 20mg/kg Q2W day 1: oxaliplatin \[85 mg/m2, 2-h infusion\] plus leucovorin \[200 mg/m2, 2-h infusion\], followed by 5-fluorouracil \[400 mg/m2, intravenous bolus; 600 mg/m2, 22-h infusion\]; day 2: leucovorin \[200 mg/m2, 2-h infusion\], followed by 5-fluorouracil \[400 mg/m2, intravenous bolus; 600 mg/m2, 22-h infusion\]

    Biological: PM8002 · Drug: FOLFOX regimen

Interventions

  • BiologicalPM8002

    PM8002 20mg/kg Q2W

  • day 1: oxaliplatin \[85 mg/m2, 2-h infusion\] plus leucovorin \[200 mg/m2, 2-h infusion\], followed by 5-fluorouracil \[400 mg/m2, intravenous bolus; 600 mg/m2, 22-h infusion\]; day 2: leucovorin \[200 mg/m2, 2-h infusion\], followed by 5-fluorouracil \[400 mg/m2, intravenous bolus; 600 mg/m2, 22-h infusion\]

06

What researchers measure

Primary outcomes

  1. Objective Response Rate

    Objective response rate (ORR) is the proportion of subjects with complete response (CR) or partial response (PR), based on RECIST v1.1.

    Time frame: Up to approximately 2 years

07

Study locations

9 sites
  • Anhui Provincial Hospital
    Hefei, Anhui, China
  • Fujian Cancer Hospital
    Fuzhou, Fujian, China
  • The First Affiliated Hospital, Sun Yat-sen University
    Guangzhou, Guangdong, China
  • Henan Cancer Hospital
    Zhengzhou, Henan, China
  • The Third Xiangya Hospital of Central South University
    Changsha, Hunan, China
  • The First Hospital of Jilin University
    Changchun, Jilin, China
  • Cancer Hospital of The University of Chinese Academy of Sciences
    Hangzhou, Zhejiang, China
  • Sir Run Run Shaw Hospital Zhejiang University School of Medicine
    Hangzhou, Zhejiang, China
  • Jinhua Municipal Centeral Hospital Medical Group
    Jinhua, Zhejiang, China
08

References and documents

Individual participant data

Plan to share: Yes — The data will be published or presented for publications (poster, abstract, articles or papers) or any presentations.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2022 to primary completion in Jul 2025, 39 months.

Of 80 industry-sponsored phase 2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 50. This study's 39 months is close to that.

Counting every sponsor, half of 429 studies reached it within 43 months; a quarter within 30 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2023
First posted
May 18, 2023
StartActual
Apr 22, 2022
Primary completionActual
Jul 24, 2025
CompletionActual
Jul 24, 2025
Last update
Jul 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05864105
Lead sponsor
Biotheus Inc.
Responsible party
Sponsor
First posted
May 18, 2023
Start date
Apr 22, 2022
Primary completion
Jul 24, 2025
Completion
Jul 24, 2025
Last update
Jul 9, 2026

Study contacts

Jieer Ying
principal investigator · Zhejiang Cancer Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pumitamig

Start the discussion